JUN 03, 2019
In this 1-Minute Video, Dr. Jeffrey Gross summarizes the 5-year outcomes from DRCR.net's Protocol S trial comparing ranibizumab with panretinal laser photocoagulation (PRP) for treatment-naive proliferative diabetic retinopathy (PDR), with or without macular edema. The previously published 2-year outcomes for the study showed the mean change in visual acuity was similar between patients who were treated with ranibizumab or laser. These long-term outcomes were similar to the 2-year findings, and support either ranibizumab or PRP as a viable treatment for PDR.
Relevant Financial Disclosures: None